

# Scientific work on the Fiix test

1. Gudmundsdottir BR, Francis CW, Bjornsdottir A, Nellbring Moa, Onundarson PT. Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. *Thromb Res* 2012;130(4):674–81.
2. Onundarson PT\*, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, Juliusson SJ, Jensdottir HM, Vidarsson B, Gunnarsson PS, Lund SH, Gudmundsdottir BR. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. *The Lancet Haematol* 2015; 2(6):e231-40. May 26, 2015. [http://dx.doi.org/10.1016/S2352-3026\(15\)00073-3](http://dx.doi.org/10.1016/S2352-3026(15)00073-3).
3. Lippi G, Favaloro EJ. Laboratory monitoring of warfarin in the era of direct oral anticoagulants (editorial comment). *The Lancet Hematology*. 2015;2(6):2
4. Letertre L, Gudmundsdottir BR, Francis CW, Gosselin RC, Skeppholm M, Malmstrom R, Moll S, Hawes E, Francart S, Onundarson, PT. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin and enoxaparin in plasma. *J Thromb Haemost* 2016; 14 (5): 1043-1053, doi: 10.1111/jth.13300.
5. Onundarson PT, Arnar DO, Lund SH, Gudmundsdottir BR, Francis CW, and Indridason OS. Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin. *Int J Lab Hematol* 2016; 38 (Suppl. 1):78–90.
6. Oskarsdóttir AR, Gudmundsdóttir BR, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, Jensdottir HM, Vidarsson B, Lund SH, Francis CW, Onundarson PT. Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. *J Thromb Thrombolysis* 2017;43(4):550-61. 10.1007/s11239-017-1482-4.
7. Jonsson PI, Gudmundsdottir BR, Francis CW, and Onundarson PT. During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time. *J Thromb Haemost* 2017; 15 (1):131-9. DOI: 10.1111/jth.13549
8. Onundarson PT, Flygenring B. Oral anticoagulant monitoring: Are we on the right track? *Int J Lab Hematol*. 2019;41(Suppl. 1):40-48. doi: 10.1111/ijlh.13008.
9. Onundarson PT, Gudmundsdottir BR. The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin. *J Thromb Thrombolysis*. 2019 Nov;48(4):685-689. doi: 10.1007/s11239-019-01928-4.
10. Oskarsdottir AR, Gudmundsdottir BR, Jensdottir HM, Flygenring BF, Palsson R and Onundarson PT. Ignoring instead of chasing after coagulation factor VII during warfarin management; an interrupted time series study. *Blood* 2021; 137 (20): 2745–2755. <https://doi.org/10.1182/blood.202008698>.
11. Witt DW. A better way to monitor warfarin therapy (editorial)? *Blood* 2021;137 (20): 2713-14.
12. Onundarson PT, Palsson R, Witt DM, Gudmundsdottir BR. Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. *Thromb J*. 2021 Oct 15;19(1):72. doi: 10.1186/s12959-021-00327-1.
13. Arnar B. Ingason MD PhD, Brynja R. Gudmundsdottir, Ragnar Palsson, Johann P. Hreinsson MD PHD, Sigrun H. Lund Ph, Loic R. Letertre, Edward Rumba, Arnar S. Agustsson, Einar S. Bjornsson MD PhD, and Pall T. Onundarson. Low incidence of thromboembolism with Fiix monitored warfarin compared to conventional warfarin and DOACs in atrial fibrillation patients. *Blood VTH* 2025;2(2): 1-12. <https://doi.org/10.1016/j.bvth.2025.100056>